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Pritzker School of Medicine, University of Chicago, United StatesSince the early 1980s, there has been clinical data demonstrating the
effects of beta-adrenergic agonist on lipid levels. Terbutalinewas shown
to raise HDL-c levels in healthy subjects after just two weeks of treat-
ment (Hooper et al., 1981). This data in conjunction with other trials
which revealed that beta-blockers lowered HDL-c and raised LDL-c as
well as triglycerides (Harvengt et al., 1987), supported the hypothesis
that stimulation of the beta-2 receptor could result in favorable lipid
changes. Maki et al. (1996) found that albuterol administration was
associatedwith favorable changes in the serum lipid proﬁle with signif-
icant lowering of LDL-c and increases in HDL-c in a small human trial
without marked impairment of glucose tolerance or its physiologic
determinants (Maki et al., 1996). Ye et al. (2015) of EBioMedicine
found that another selective beta-2 agonist, R-bambuterol also signiﬁ-
cantly lowered LDL-c in a relatively small healthy volunteer population
(Ye et al., 2015). Since the racemic mixture of bambuterol was not
effective in modifying the lipid levels, this suggests that there may be
inhibitory effects between R and S bambuterol on the beta-2 receptors
that regulate lipoprotein metabolism, Therefore, there is compelling
hypothesis generating human data that selective beta-2 agonist may
have beneﬁcial effects on lipid metabolism.
Beta-2 agonism stimulates intracellular cAMP,which regulates a num-
ber of pathways involved in lipid and glucose metabolism. Sterol regula-
tory element-binding proteins (SREBPs) are major transcription factors
regulating the biosynthesis of cholesterol, fatty acids and triglycerides
(Xiao and Song, 2013). SREBP is controlled by cAMP, which may explain
why beta-2 agonismmay affect LDL-c, HDL-c and triglyceride. In addition,
cAMP stimulates ABCA1 upregulation, which results in HDL mediated
cholesterol efﬂux from macrophages or hepatocytes (Fournier et al.,
2003).
Statin therapy andmore recently PCSK9monoclonal antibodies have
demonstrated robust efﬁcacy for lowering LDL-c but there remains
signiﬁcant unmetmedical need especially for patients that are refracto-
ry or intolerant to these treatment. A recent study, found that of 647
patients with coronary heart disease prescribed statins, about 20% failed
to have a signiﬁcant LDL-lowering response to treatment, and insteadDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.02.006.
http://dx.doi.org/10.1016/j.ebiom.2015.03.004
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article undersaw LDL-cholesterol levels increased 6.2%, compared to a drop of
44.5% among those who responded to the treatment (Kataoka et al.,
2015). In addition, approximately 10% of dyslipidemic patients are
statin intolerant (Jacobson, 2014). SREBP is an important target for
novel drug development and this new clinical data by Ye and colleagues
may provide helpful insights into role of beta-2 agonism in lipid metab-
olismwhichmay provide another class of agents that address an unmet
clinical need in patients with dyslipidemia (Ye et al., 2015).
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